Digoxin Reduces Heart Failure Risk in Rheumatic Heart Disease

Rheumatic heart disease remains a leading cause of cardiovascular morbidity and mortality in many parts of the world, often culminating in progressive heart failure and complex valvular dysfunction [1, 2]. Although contemporary guidelines offer clear direction for managing heart failure and atrial fibrillation, patients with rheumatic etiologies are frequently underrepresented in the landmark trials that inform these standards [3, 4]. In clinical practice, rate control is a cornerstone of therapy for the atrial fibrillation that commonly complicates rheumatic mitral stenosis, yet the long-term effects of specific agents on survival and disease progression have been poorly defined [5, 6]. Digoxin is often used in these settings due to its low cost and wide availability, but its role has been supported more by physiological rationale than by high-quality randomized evidence [2, 7]. A new multicenter, placebo-controlled trial was designed to address this critical evidence gap, providing definitive data on how this established inotropic and chronotropic agent affects clinical outcomes in symptomatic rheumatic heart disease.